For example, there are FDA-approved treatments (e.g., erlotinib, gefitinib, and Osimertinib) for the receptor tyrosine kinases (RTKs) family members, such as epidermal growth factor receptor (EGFR), which is hyperactivated or mutated in NSCLC patients [30, 31]. Here, EGFR is linked to non-small cell lung carcinoma.